Allakos/ALLK

$1.64

10.81%
-
1D1W1MYTD1YMAX

About Allakos

Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. It is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Ticker

ALLK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Alexander

Employees

123

Headquarters

San carlos, United States

Allakos Metrics

BasicAdvanced
$143.46M
Market cap
-
P/E ratio
-$1.93
EPS
0.82
Beta
-
Dividend rate

What the Analysts think about Allakos

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 5 analysts.
76.83% upside
High $7.00
Low $1.00
$1.64
Current price
$2.90
Average price target

Allakos Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-45.6M
29.91%
Profit margin
0%
-

Allakos Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.99%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.50
-$0.49
-$0.41
-$0.52
-
Expected
-$0.57
-$0.49
-$0.48
-$0.45
-$0.47
Surprise
-11.73%
-0.25%
-14.46%
14.99%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Allakos stock

Buy or sell Allakos stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing